New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

32

Gilead’s Lenacapavir Shows Promise for Multidrug-Resistant HIV in Phase II/III Trial

Topline results from Gilead Sciences’ Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.

35

U.S. COVID deaths top 250,000 as New York City schools halt in-person classes

The U.S. death toll from Covid-19 surpassed a grim new milestone of 250,000 lives lost as New York City’s public school system – the nation’s largest – called a halt to in-classroom instruction, citing a jump in coronavirus infection rates.

36

Liguori Academy and CMI/Compas Partner to Build Library for Students

Liguori Academy and CMI/Compas Partner to Build Library for Students PHILADELPHIA – November 18, 2020 – Liguori Academy, a nonprofit private high school committed to serving the community, has launched a campaign to build a library for its students, with the support of longtime partner CMI/Compas, strategic media agency and part of WPP (NYSE:WPP). The […]

40

Fast Track, Breakthrough and Priority Reviews: Sanofi and ViiV

The U.S. Food and Drug Administration granted various designations for Sanofi’s avalglucosidase alfa for Pompe disease, Sanofi’s rilzabrutinib for immune thrombocytopenia, and ViiV Healthcare’s cabotegravir for HIV prevention.